Cargando…

Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru

BACKGROUND: The clinical and economic burden associated with invasive and non-invasive pneumococcal and non-typeable Haemophilus influenzae (NTHi) diseases is substantial in the Latin America and Caribbean region, where pneumococcal vaccines have only been introduced to a few countries. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez, Jorge Alberto, Tirado, Juan Carlos, Navarro Rojas, Aldo Amador, Castrejon Alba, Maria Mercedes, Topachevskyi, Oleksandr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228443/ https://www.ncbi.nlm.nih.gov/pubmed/24171921 http://dx.doi.org/10.1186/1471-2458-13-1025

Ejemplares similares

Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model
por: Bakır, Mustafa, et al.
Publicado: (2012)

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
por: Mangen, Marie-Josée J., et al.
Publicado: (2015)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option
por: Dorji, Kinley, et al.
Publicado: (2018)

A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries
por: Martí, Sebastián García, et al.
Publicado: (2013)

Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis
por: Chen, Cynthia, et al.
Publicado: (2018)

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities
por: Li, Yan, et al.
Publicado: (2021)

Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications
por: Pecenka, Clint, et al.
Publicado: (2021)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
por: Kim, Hye-Young, et al.
Publicado: (2020)

Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
por: Ordóñez, Jaime E, et al.
Publicado: (2014)

Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine
por: Herbert, Jenny A., et al.
Publicado: (2018)

Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia
por: Perdrizet, Johnna, et al.
Publicado: (2021)

Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
por: Polistena, Barbara, et al.
Publicado: (2022)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey
por: Sevilla, J. P., et al.
Publicado: (2020)

Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions
por: Edmondson-Jones, Mark, et al.
Publicado: (2021)

Effectiveness and cost-effectiveness of general immunisation of infants and young children with the heptavalent conjugated pneumococcal vaccine
por: Antony, Katja, et al.
Publicado: (2005)

Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools
por: Chaiyakunapruk, Nathorn, et al.
Publicado: (2011)

Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia
por: Ordóñez, Jaime E, et al.
Publicado: (2015)

Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom
por: Wilson, Michele, et al.
Publicado: (2023)

1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
por: Rozenbaum, Mark, et al.
Publicado: (2023)

The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
por: Feldman, Charles, et al.
Publicado: (2020)

Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines
por: Haasis, Manuel Alexander, et al.
Publicado: (2015)

Letter to the Editor Regarding: “Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants”
por: Gomez, Jorge A., et al.
Publicado: (2022)

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
por: Earnshaw, Stephanie R, et al.
Publicado: (2012)

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England
por: van Hoek, Albert Jan, et al.
Publicado: (2016)

Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
por: Shen, Kunling, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Routine Use of 15-Valent Pneumococcal Conjugate Vaccine in the US Pediatric Population
por: Huang, Min, et al.
Publicado: (2023)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
por: Ngamprasertchai, Thundon, et al.
Publicado: (2023)

The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru
por: Cárdenas, María Kathia, et al.
Publicado: (2015)

Cost-utility analysis of a universal pneumococcal vaccination programme for older adults in Norway
por: Nymark, Liv Solvår, et al.
Publicado: (2022)

Conjugation dynamics depend on both the plasmid acquisition cost and the fitness cost
por: Prensky, Hannah, et al.
Publicado: (2021)

Impact of pneumococcal conjugate vaccine uptake on childhood pneumonia mortality across income levels in Brazil, Colombia, and Peru
por: Shioda, Kayoko, et al.
Publicado: (2020)

Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
por: Kuhlmann, Alexander, et al.
Publicado: (2012)

Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Kenyan Children
por: Ayieko, Philip, et al.
Publicado: (2013)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

Novel Low-Cost Thermotherapy for Cutaneous Leishmaniasis in Peru
por: Valencia, Braulio M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t2t5933sm5sha57vtqe4orpnkb